ArticlePloS one2026
Systematic analysis of global O-serotype prevalence of neonatal extraintestinal pathogenic Escherichia coli: A protocol integrating previous research and bioinformatics databases.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal extraintestinal pathogenic Escherichia coli (ExPEC) severe threat to newborn health. O antigen is a highly variable component of lipopolysaccharide, serves as the main phenotypic marker for serotyping, and represents a promising target for vaccination. The global distribution of O-serotypes in neonatal ExPEC remains unclear, limiting epidemiological understanding and vaccine development.
methodsThis study will integrate literature and genomic data to analyze the global distribution of O-serotypes in neonatal ExPEC systematically. We will systematically search PubMed, Embase, Web of Science, and Scopus for studies reporting neonatal ExPEC serotypes and published between database inception and December 2026. In parallel, neonatal ExPEC genomes will be retrieved from NCBI BioSample, ENA, and CNCB. Strain-level data, including serotype, host age, host disease, isolation site, isolation year, and geography, will be extracted. Serotypes from genomic data will be predicted using multiple bioinformatics tools. The primary outcome is global serotype prevalence; secondary outcomes include temporal trends, geographical variation, and associations with clinical syndromes. Risk of bias will be assessed at both study and strain levels. Descriptive synthesis will integrate literature and genome data, and subgroup or sensitivity analyses will explore heterogeneity if substantial. DISCUSSION: This study will clarify whether neonatal ExPEC is consistently driven by a limited number of dominant O-serotypes or whether substantial temporal and geographical heterogeneity exists. Defining these patterns is essential for evaluating the feasibility of O-antigen-targeted vaccines, particularly whether broad multivalent strategies or region-specific approaches are more appropriate. By integrating literature and genomic data, this study may also improve understanding of serotype associations with specific invasive syndromes, including sepsis and meningitis. The findings will provide a clearer epidemiological basis for vaccine prioritization, surveillance strategies, and future neonatal ExPEC research in the context of increasing antimicrobial resistance. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD420251140604.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.